Physician
Oncology
Dr. Jorge E. Romaguera, MD
|
|
Give Review
Jorge Romaguera practices Oncology. He went to University of Puerto Rico School of Medicine. He over the years received 3 awards: "America's Top Doctors", "Top Doctors:SE Texas" and "America's Top Doctors for Cancer". Jorge E. Romaguera, MD is a published doctor. He has 58 publications published. The most current publication "Hedgehog inhibitors selectively target cell migration and adhesion of mantle cell lymphoma in bone marrow microenvironment." Jorge E. Romaguera accepts Medicare payments and is listed with Medicare.gov.
Publications
- Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review.
- Hedgehog inhibitors selectively target Cell migration and adhesion of mantle Cell lymphoma in bone marrow microenvironment.
- The effect of different rituximab-containing chemotherapy strategies on hepatitis C viremia.
- Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-Cell lymphoma.
- Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory Lymphoma.
- Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin Lymphoma.
- Patients with mantle Cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes.
- Radiation therapy is an effective modality in the treatment of mantle Cell lymphoma, even in heavily pretreated patients.
- Safety and activity of lenalidomide and rituximab in untreated indolent Lymphoma: an open-label, phase 2 trial.
- Pegylated Liposomal Doxorubicin Replacing Conventional Doxorubicin in Standard R-CHOP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma: An Open Lab...
- Clinical outcomes of a novel combination of lenalidomide and rituximab followed by stem Cell transplantation for relapsed/refractory aggressive B-Cell non-hodgkin lymp...
- Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-Cell non-Hodgkin lymphoma.
- (90) Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-Cell lymphomas, including bulky disease.
- Current regimens and novel agents for mantle Cell lymphoma.
- Double hit lymphoma: the MD Anderson Cancer Center clinical experience.
- Indolent peripheral T-Cell lymphoma involving the gastrointestinal tract.
- Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular Lymphoma: a single group, open-label, phase 2 trial.
- The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin Lymphoma.
- Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse larg...
- Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma.
- Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin...
- Targeting BTK with ibrutinib in relapsed or refractory mantle-Cell lymphoma.
- The use of salivary protein secretions as an in vivo model to study mantel Cell lymphoma progression and treatment.
- Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-Cell lymphoma.
- Oral lenalidomide with rituximab in relapsed or refractory diffuse large Cell, follicular and transformed lymphoma: a phase II clinical trial.
- Zoledronic acid for prevention of bone loss in patients receiving primary therapy for Lymphomas: a prospective, randomized controlled phase III trial.
- Role of the microenvironment in mantle Cell lymphoma: IL-6 is an important survival factor for the tumor Cells.
- Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Sub...
- Verapamil synergistically enhances cytotoxicity of bortezomib in mantle Cell lymphoma via induction of reactive oxygen species production.
- Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/R...
- A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.
- Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-Cell lymphoma: a phase 1/2 clinical trial.
- Clinical experience with the heat shock protein-90 inhibitor, tanespimycin, in patients with relapsed Lymphoma.
- Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Chemotherapy with Interferon for Advanced Stage Classic Hodgkin's Lymphoma: A 10-Year Follow-up Study.
- HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle Cell lymphoma.
- Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin Lymphoma: phase 1 stud...
- Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle Cell lymphoma.
- Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle Cell lymphoma treated with hyper-CVAD and rituximab, alternating with r...
- Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal ly...
- Proliferation predicts failure-free survival in mantle Cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin,...
- Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle Cell lymphoma.
- Mantle Cell lymphoma: Frontline and salvage therapy.
- Follicular dendritic Cell sarcoma: a report of 14 cases and a review of the literature.
- Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B Cell...
- High rate of durable remissions after treatment of newly diagnosed aggressive mantle-Cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-...
- A prospective randomized study to compare the molecular response rates between Central lymphatic irradiation and intensive alternating triple chemotherapy in the treat...
- The utility of interphase fluorescence in situ hybridization for the detection of the translocation t(11;14)(q13;q32) in the diagnosis of mantle Cell lymphoma on fine-...
- Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-Cell non-Hodgkin's lymphoma.
- Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma.
- Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's Lymphoma and Hodgkin's disease.
- Evaluation of peripheral blood involvement of mantle Cell lymphoma by fluorescence in situ hybridization in comparison with immunophenotypic and morphologic findings.
- Frequency of gastrointestinal involvement and its clinical significance in mantle Cell lymphoma.
- International prognostic index-based outcomes for diffuse large B-Cell lymphomas.
- Results with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone followed by radiotherapy with or without prechemotherapy surgical deb...
- Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple Myeloma: a feasibility study.
- Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B Cell lymphoma: current data on safety and efficacy.
- Nuclear Translocation of B-Cell-Specific Transcription Factor, BACH2, Modulates ROS Mediated Cytotoxic Responses in Mantle Cell Lymphoma.
Schools
Univ Of Pr Sch Of Med
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Plasmapheresis
- Prostate Cancer Screening Exam (DRE)
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Basal Cell Carcinoma
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- Top Doctors:SE Texas
- America's Top Doctors for Cancer
Education
-
University of Texas MD Anderson Cancer Center -
University of Puerto Rico -
University of Puerto Rico School of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1003911363 | |
| NPPES Provider LastName | ROMAGUERA | |
| NPPES Provider FirstName | JORGE | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 518.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 21.0 | |
| Percent Opioid Claims | 4.05 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1003911363 |
| Last Name Of The Provider | ROMAGUERA |
| First Name Of The Provider | JORGE |
| View All |
Similar Doctors
|
|
Dr. Scott E. Woodman, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Nadya Hasham-Jiwa, DO
This Doctor is OpenDoctor Recommended.
|
|
Dr. Harry R. Price, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Saraswati P. Reddy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Syed U. Akhtar, MD |
|
|
Dr. Joseph A. Ludwig IV, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Celyne Bueno-Hume, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nuhad K. Ibrahim, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Zahida Yasin, MD
This Doctor is OpenDoctor Recommended.
|